Evommune, Inc. (EVMN) Stock Statistics & Valuation Metrics

Evommune, Inc. has a market cap or net worth of $597.07M. The enterprise value is $474.73M.

Evommune, Inc. has 31,524,094 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evommune, Inc.’s return on equity (ROE) is 0.46 and return on invested capital (ROIC) is -142.62%.

The current PE Ratio of Evommune, Inc. is ―. Evommune, Inc.’s PEG ratio is -0.09.

In the last 12 months, Evommune, Inc. had revenue of 7.00M and earned -66.81M in profits. Earnings per share was -2.27.

In the last 12 months, operating cash flow was -82.11M and capital expenditures -131.00K, giving a free cash flow of -82.24M billion.

Evommune, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Evommune, Inc. upcoming earnings date is Dec 11, 2025, After Close (Confirmed).

Evommune, Inc. as a current ratio of 2.64, with Debt / Equity ratio of -140.75%

In the past 12 months, Evommune, Inc. has paid 0.00 in taxes.

Evommune, Inc. EV to EBITDA ratio is -12.00, with an EV/FCF ratio of -13.48.

Evommune, Inc. has $76.06M in cash and marketable securities with $257.77M in debt, giving a net cash position of -$181.71M billion.

Gross margin is 91.82%, with operating margin of -1000.19%, and net profit margin of -954.40%.

The average price target for Evommune, Inc. is $39.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy